Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease

Oxford IBD Cohort Investigators(University of Oxford), Nathaniel R. West(University of Oxford), Ahmed N. Hegazy(University of Oxford), Benjamin M. J. Owens(University of Oxford), Samuel J. Bullers(University of Oxford), Bryan Linggi(University of Oxford), Sofia Buonocore(University of Oxford), Margherita Coccia(University of Oxford), Dieter Görtz(University of Oxford), Sébastien This(University of Oxford), Krista Stockenhuber(University of Oxford), Johanna Pott(University of Oxford), Matthias Friedrich(University of Oxford), Grigory Ryzhakov(University of Oxford), Frédéric Baribaud(Janssen (United States)), Carrie Brodmerkel(Janssen (United States)), Constanze Cieluch(Rutherford Appleton Laboratory), Nahid Rahman(Research Complex at Harwell), Gerhard Müller‐Newen(Rutherford Appleton Laboratory), Raymond J. Owens(Centre for Human Genetics), Anja A. Kühl(University of Oxford), Kevin J. Maloy(University of Oxford), Scott E. Plevy(University of Oxford), Satish Keshav(University of Oxford), Simon Travis(University of Oxford), Fiona Powrie(University of Oxford)
Nature Medicine
April 3, 2017
Cited by 790Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis